In a filing, Vir Biotechnology Inc revealed its Director SATO VICKI L unloaded Company’s shares for reported $0.11 million on Sep 02 ’25. In the deal valued at $4.99 per share,22,000 shares were sold. As a result of this transaction, SATO VICKI L now holds 1,254,391 shares worth roughly $6.5 million.
Then, SATO VICKI L sold 22,000 shares, generating $109,699 in total proceeds. Upon selling the shares at $4.99, the Director now owns 1,276,391 shares.
Before that, Eisner Mark sold 6,796 shares. Vir Biotechnology Inc shares valued at $37,162 were divested by the EVP and Chief Medical Officer at a price of $5.47 per share. As a result of the transaction, Eisner Mark now holds 108,204 shares, worth roughly $0.56 million.
Evercore ISI initiated its Vir Biotechnology Inc [VIR] rating to an Outperform in a research note published on September 03, 2025; the price target was $12. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “a Buy”. JP Morgan also remained covering VIR and has decreased its forecast on January 29, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. BofA Securities revised its rating on September 08, 2023. It rated VIR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of VIR
On Friday, Vir Biotechnology Inc [NASDAQ:VIR] saw its stock unchanged to $5.18. Over the last five days, the stock has gained 3.60%. Vir Biotechnology Inc shares have fallen nearly -34.68% since the year began. Nevertheless, the stocks have fallen -29.43% over the past one year.
How much short interest is there in Vir Biotechnology Inc?
A steep rise in short interest was recorded in Vir Biotechnology Inc stocks on 2025-08-29, growing by 0.79 million shares to a total of 11.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 11.14 million shares. There was a rise of 6.58%, which implies that there is a positive sentiment for the stock.